canakinumab
Sign in to saveAlso known as ACZ885, ACZ-885, Ilaris
Canakinumab, sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis, active Still's disease, including adult-onset Still's disease, gout flares. It is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.
In the Vinony graph
Within Vinony's link graph, canakinumab is referenced by 398 other articles, and connects out to monoclonal antibody, Interleukin 2 and familial Mediterranean fever.
Vinony files it under Antineoplastic drugs, Chemicals that do not have a ChemSpider ID assigned and Drugboxes which contain changes to verified fields.
Its subject is documented across 18 Wikipedia language editions.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 460015774
- Drug.image
- Canakinumab bound to IL-1β.png
- Drug.type
- mab
- Drug.caption
- Ribbon diagram of canakinumab (blue) bound to IL-1β (yellow) from PDB entry
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- IL-1β
- Drug.tradename
- Ilaris
- Drug.MedlinePlus
- a622024
- Drug.DailyMedID
- Canakinumab
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- Intravenous, subcutaneous
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AC08
- Drug.legal_AU
- S4
- Drug.legal_US
- Rx-only
via Wikipedia infobox
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Antibody
- First approval
- 2009
- Admin. routes
- parenteral
- Indications
- juvenile idiopathic arthritis, gout, Fever, Pyoderma
via ChEMBL · EBI
Research
1,370 papers- Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.The New England journal of medicine · 2018
- Canakinumab.mAbs · 2010
- Canakinumab for secondary prevention of coronary artery disease.Future cardiology · 2021
- Canakinumab for the treatment of adult-onset Still's disease.Expert review of clinical immunology · 2020
- Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.Annals of the rheumatic diseases · 2012
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 4 more facts
- World Health Organisation international non-proprietary name
- canakinumab
- defined daily dose
- 2.7
- has characteristic
- biopharmaceutical
- subject has role
- monoclonal antibody
via Wikidata · CC0
~5 min read
Encyclopedic overview
5 sectionsContents
- Medical uses
- Adverse effects
- History
- References
- External links
Canakinumab, sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis, active Still's disease, including adult-onset Still's disease, gout flares. It is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.
Common side effects include infections (colds and upper respiratory tract infections), abdominal pain and injection-site reactions.
Excerpted from Wikipedia’s “canakinumab” article, available under the CC BY-SA 4.0 licence.